Royalty Pharma (RPRX) PT Raised to $67 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Price: $66.40 --0%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn raised the price target on Royalty Pharma (NASDAQ: RPRX) to $67.00 (from $65.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Royalty Pharma reports third quarter 2026 results
- Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR56 at BMO Capital
- Gujarat Fluorochemicals Ltd (FLUOROCH:IN) PT Raised to INR5,100 at Axis Capital Limited
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
